FINANCINGS

Anaptysbio Inc. closed its IPO of 5.75 million shares of its common stock at $15 each, which includes the exercise in full by the underwriters of their option to purchase an additional 750,000 shares.

Arix Bioscience Ltd. is to float on the main market of the London Stock Exchange, raising up to $125.6 million to form and fund drug discovery and development companies from startup to maturity.

Athersys Inc. closed its public offering for gross proceeds of about $23 million.

Cerecor Inc. entered an equity distribution agreement where it may offer and sell shares of its common stock having an aggregate gross sales price of up to $12 million.

Corium International Inc. priced its public offering of about 6.7 million shares at $3 per share for expected gross proceeds of about $20 million.

Fortress Biotech Inc. subsidiary Mustang Bio Inc. closed on a $94.5 million private placement financing.

Jounce Therapeutics Inc. priced an upsized offering of 6.365 million shares at $16 each for proceeds of $101.8 million.

Rigel Pharmaceuticals Inc. priced its public offering of 20 million shares of common stock at $2 each for gross proceeds of about $40 million.

Synergy Pharmaceuticals Inc. priced its underwritten public offering of 20.3 million shares of its common stock at $6.15 each.

Tarveda Therapeutics Inc. said it completed a $30 million series D financing.

Vividion Therapeutics Inc. has launched with a $50 million series A investment.

DEALS

Calithera Biosciences Inc. is partnering with Incyte Corp. for small-molecule arginase inhibitor CB-1158, and will collect $45 million up front and an $8 million equity investment and $430 million in potential milestone payments.

Eli Lilly and Co. is exiting its alliance on type 1 and type 2 diabetes with Adocia SA.

Exelixis Inc. and Takeda Pharmaceutical Co. Ltd. have signed an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, Exelixis' lead oncology medicine.

Genomedx Biosciences Inc. inked a research collaboration with Astellas Pharma Inc., which will furnish tumor samples from its phase II ENACT trial in prostate cancer for Genomedx to profile using its Decipher Classifier and Decipher GRID (genomics resource information database).

Indivumed GmbH signed an agreement providing Regeneron Pharmaceuticals Inc. with access to its tissue sample and clinical and molecular data collection methods, to support the company's cancer research programs.

Nemus Bioscience Inc. signed a research agreement with the University of Mississippi to further explore the analgesic and abuse-deterrent properties of NB2111, a cannabidiol analogue.

Neurotrope Inc. signed a licensing agreement with Stanford University for an accelerated synthesis of brystatin-1, a complex marine natural product with 11 chiral centers. The company is developing brystatin-1 for Alzheimer's disease.

Opko Health Inc. said its subsidiary, Genedx, made a collaborative agreement with the Wellcome Trust Sanger Institute to participate in the Deciphering Developmental Disorder study.

Spero Therapeutics LLC acquired a next-generation set of antibacterial compounds from Pro Bono Bio Ltd.

. . . AND MORE

Astrazeneca plc said the FDA approved Symbicort (budesonide/formoterol fumarate dihydrate) inhalation aerosol 80/4.5 mcg to treat asthma in patients 6 up to 12 years.

Avexis Inc. said the EMA granted priority medicines (PRIME) program access for gene therapy AVXS-101 for the treatment of spinal muscular atrophy type 1.

Biogen Inc. completed the launch of its public company spinout, Bioverativ Inc., which has emerged with two profitable products and a pipeline of candidates in hemophilia and rare blood diseases.

Catabasis Pharmaceuticals Inc.'s shares tumbled 70.7 percent as top-line data from a proof-of-concept trial of its Duchenne muscular dystrophy candidate edasalonexent (CAT-1004) showed that 12 weeks of treatment with the NF-kB inhibitor failed to significantly impact a biomarker indicative of benefits in lower leg muscle composition and inflammation in boys with the fatal condition.

Janssen Research & Development LLC, a unit of Johnson & Johnson, said it has established several collaborations through its Janssen Human Microbiome Institute, which are focused on advancing the discovery, development and commercialization of next-generation microbial products.

Sunovion Pharmaceuticals Inc. said the FDA approved the supplemental NDA for Latuda (lurasidone) for the treatment of schizophrenia in adolescents ages 13 to 17.

Targovax ASA shares surged on preliminary top-line data indicating a possible survival benefit in pancreatic cancer for its peptide-based therapeutic vaccine TG01, in development for Ras-mutated cancers.

Tenax Therapeutics Inc.'s shares fell 76.4 percent on news that its lead candidate, levosimendan, failed to meet the co-primary endpoints of a phase III study evaluating its potential for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome.

Uniqure NV said AMT-060, its investigational gene therapy in patients with severe hemophilia B, has received FDA breakthrough therapy designation.